104 results about "Treatment sleep" patented technology

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Techniques for addressing sleep disorders are provided. A system includes a nerve stimulator that is configured to deliver stimulation energy to a nerve of a sleeping patient. A system includes a sensor for gather data from the sleeping patient and a controller for processing the data. The controller is configured to cause the stimulation energy that is provided to be adjusted based on the sensed data.

A medical device is provided that can be used to determine the optimal parameters for the detection of respiratory activity and the best modality for the modulation of the nervous system and / or respiratory muscles in response. Related systems and algorithms for programming the device, as well as the design parameters, are provided.

A device includes at least one first element in operative relation to at least one target tissue from a set of target tissues to treat sleep disordered breathing, which may include obstructive sleep apnea. The operative relation may include sensing and / or stimulation. The at least one target tissue may comprise diaphragm-related tissue, respiratory tissue-related nerves, and / or upper airway patency-related tissue. Example tissue in the set of target tissues includes hypoglossal nerve, infrahyoid muscle (IHM)-innervating nerve, IHMs, glossopharyngeal nerve, an internal superior laryngeal (iSL) nerve, phrenic nerve, diaphragm, pudendal nerve, among other nerves and muscles. In some example, multiple target tissue may be selected for stimulation and / or sensing.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Provided are systems, methods, and devices for providing mediation or alleviation of sleep disorders and insomnia. Systems may include an interface, processing devices, and a controller. The interface is configured to obtain measurements from a brain of a user with sleeping disorders and insomnia. A first processing device is configured to generate multiple brain state parameters characterizing one or more features of a brain state of the user. A second processing device is configured to generate models of the brain of the user based on the plurality of brain state parameters and the plurality of measurements, and determine, using the models and training data comprising one or more mediation data points, a mediation procedure for reducing one or more symptoms of the sleeping disorder or insomnia. The mediation procedure is provided to one or more entities, and one or more control signals are generated by the controller based on the mediation procedure.

To provide oral appliances that can be used to treat sleep apnea syndrome (SAS) ranging from mild to severe. [Solution] One embodiment of an oral appliance for sleep apnea is an oral appliance that is fitted into the user's oral cavity. The oral appliance comprises an upper jaw portion, a lower jaw portion, and a drive unit. The upper jaw portion has a shape that mimics the user's upper teeth and contacts the upper teeth. The lower jaw portion has a shape that mimics the user's lower teeth and contacts the lower teeth. The drive unit connects the upper jaw portion and the lower jaw portion so as to be able to change the relative position of the lower jaw portion with respect to the upper jaw portion, and drives the lower jaw portion. The drive unit has a control circuit that determines whether the user is in a state of apnea based on sensor information obtained from a sensor that detects the user's apnea state, and if the user is in a state of apnea, drives the lower jaw portion toward the user's forward position, and if the user is not in a state of apnea, drives the lower jaw portion to return to the user's resting position.

An oral appliance may include a mouthpiece configured to be positioned in an oral cavity of a user and an electronic assembly coupled to the mouthpiece. The electronic assembly may include an oxygen sensor oriented toward soft tissue of the user's mouth to determine an oxygen saturation level of the user. The electronic assembly may be positioned within an appendage extending away from a wall of the mouthpiece.

The present specification is directed a method manufacturing a patient interface for treatment of sleep disordered breathing using air pressure by delivery of air to a patient's airway. The method includes locating a shell, a first sub section of a seal forming structure, and a first section of the seal forming structure in a tool. The first sub section includes a groove. The first section is constructed from a thermoformable material. The method further includes introducing a moulding material to the tool and overmolding the shell, the first sub section, and the first section. The moulded material forms a second sub section of the seal forming structure that connects the first sub section to the shell and fully encloses the first section within the groove.

The invention discloses an application of a CHRNA3 agonist in treatment of sleep disorders. The application finds that the CHRNA3 agonist varenicline can effectively relieve the sleep disorder reaction for the first time, on this basis, the invention provides a new application of the CHRNA3 agonist varenicline in treating the sleep disorder, and meanwhile, provides a method for screening candidate drugs for treating diseases caused by hypoxia stress, and provides a new application of the CHRNA3 agonist varenicline in treating the sleep disorder. A new treatment means is provided for sleep disorder, especially sleep disorder caused by hypoxia stress.

The invention relates to a cerebroprotein peptide and casein hydrolysate composition and application thereof in improving sleep and memory, and belongs to the technical field of biological protein peptides. According to the preparation method disclosed by the invention, Maillard modification of the casein enzymolysis primary product is realized by screening the enzymolysis protease of the bovine milk casein and screening the carbonyl compound which is subjected to Maillard reaction with the casein enzymolysis primary product, so that the reducing power, the metal ion chelating capacity and the antioxidant capacity of the casein hydrolysate are effectively improved; furthermore, free radicals in the body are removed, oxidative stress reaction is relieved, and a good foundation is laid for improving sleep quality. The brain protein peptide and the casein hydrolysate are compounded, so that the sleep latency can be effectively shortened, the sleep rate can be increased, the sleep can be effectively improved, the content of dopamine and noradrenaline in hypothalamus can be reduced, the content of 5-hydroxytryptamine and the content of aminobutanoin can be increased, and the brain protein peptide composition has good effects of relieving and treating sleep disorders and improving memory.

The present technology generally relates to methods for addressing sleep apnea in a patient. At least some of the methods may include one or more of percutaneously inserting an implantable signal delivery device at an insertion point on a patient's neck, moving the signal delivery device in a medial-to-lateral direction toward a neck loop nerve of the patient, and implanting the signal delivery device at a target location at least proximate the neck loop nerve. The signal delivery device may include at least one electrode positioned to deliver a modulation signal to tissue, such as a portion of a neck loop nerve, at least proximate to a target location. In some embodiments, delivery of the modulation signal may induce a patient's trailing-side traction, thereby addressing sleep apnea in the patient.

The present disclosure relates to a composition for preventing, ameliorating or treating sleep disorder or insomnia, which contains an extract of a roasted citrus byproduct as an active ingredient. The extract of a roasted citrus byproduct of the present disclosure has very excellent effect of decreasing sleep latency, increasing sleep duration and increasing non-REM sleep. In addition, the composition of the present disclosure, which contains ingredients derived from the naturally occurring citrus byproduct, can ensure safety without inducing the side effects of synthetic drugs including pentobarbital and benzodiazepine and with no side effects such as cognitive impairment, tolerance or dependency even after long-term use. Accordingly, the composition for preventing, alleviating or treating sleep disorder, which contains an extract of a roasted citrus byproduct as an active ingredient, of the present disclosure is very useful for preparation of a food composition and a pharmaceutical composition.

The invention discloses a method for establishing a bee sleep rhythm injury model, which is characterized by comprising the following steps of: animal selection: selecting a mature bee as an object for establishing the bee sleep rhythm injury model; preparing a caffeine cane sugar solution: dissolving caffeine in the sterile cane sugar solution to prepare the caffeine cane sugar solution; and model establishment: performing light-dark alternate culture on mature bees and feeding the bees with the caffeine sucrose solution to establish the bee sleep rhythm injury model. The invention further discloses application of the germ bee sleep rhythm injury model and / or the sleep rhythm injury sterile bee model established by the method. The method is easy and convenient to operate, low in cost, short in modeling period, remarkable in sleep rhythm injury symptom and adjustable in disease degree, and the established bee sleep rhythm injury model can be used for screening new methods or new drugs for preventing or treating sleep rhythm injury related diseases.

The invention relates to (i) the prevention or treatment of a sleep disturbance, preferably in a patient having neuropathic pain; and / or (ii) the prevention or treatment of neuropathic pain in a patient having a sleep disturbance; and / or (iii) the prevention or treatment of neuropathic pain in a patient having been treated previously and / or being treated concomitantly with an analgesic medication for relief of neuropathic pain, preferably selected from antiepileptics, antidepressants and opioid analgesics, wherein the patient preferably has a sleep disturbance; in either cases by means of one or more high-concentration capsaicin and / or capsaicinoid topical dose units, preferably pharmaceutical patches, comprising capsaicin and / or capsaicinoid at a concentration of at least 2.5 wt.-%, relative to the total weight of dose unit.

An oral appliance (10) for treating sleep apnea in a user, comprising a dental tray (20) configured to be placed in the oral cavity of the user, a processor, and at least one sensor coupled to the dental tray. According to an aspect, the processor can be configured to detect a condition of the user based on data generated by the at least one sensor. Further, the sensor can comprise at least one of a sound measuring device, an inertial measurement unit, a pulse oximeter, or an electroencephalogram.

In general, the invention relates to pharmaceutical compositions comprising (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI) and methods of treating Sleep Apnea comprising administering (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI). In some embodiments, the NRI is atomoxetine.

In general, the invention relates to pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI), muscarinic receptor antagonist, and carbonic anhydrase inhibitor and methods of treating Sleep Apnea comprising the administration of these pharmaceutical compositions.

Devices and / or methods for treating sleep disordered breathing may include stimulation of a single nerve, multiple nerves, as well as other tissues relating to upper airway patency.

The invention provides a transcranial magnetic stimulation treatment sleep disorder data analysis method, which comprises the following steps of: identifying a conversion process of sleep maintenance capability from continuous improvement to a stable plateau phase according to a sleep improvement degree in an early stage of consolidation and a synaptic connection daily attenuation degree, and determining a key turning time point when a transcranial magnetic stimulation treatment effect reaches a peak value; according to the weakening degree of the short interval treatment on the synaptic connection stability, the consolidation later-stage recovery blocking degree and the sleep time, the weekly decline time of the sleep maintaining ability is recognized, and a sleep ability decline record is obtained; dividing and integrating the key turning time point and the sleep ability decline record according to the adjusted treatment stage, evaluating the transcranial magnetic stimulation treatment effect improvement degree of the chronic insomnia patient, and obtaining an overall treatment response evaluation result.

This product is the main unit of a positive airway pressure (CPAP) device, which is used, for example, in the treatment of sleep apnea syndrome (SAS). A positive airway pressure (CPAP) device, also known as a CPAP device, works by supplying pressurized air to the user's airway to prevent apnea during sleep, thereby reducing snoring and improving sleep quality. The main unit has a hose connection port, and a hose with a mask attached is connected to it.

A method for treating sleep apnea provides an implantable device having at least one layer of piezoelectric material sandwiched by an outer electrode and an inner electrode, implanting the implantable device inside the tongue of a patient, and generating electricity when the implantable device deforms, such that the electricity flows to the hyoglossus nerve to stimulate it, thereby moving the tongue to open the upper airway of the patient.

Described are compositions comprising a compound of formula I: in which R represents H, or optionally substituted C1-15 alkyl, C1-15 alkenyl or C1-15 alkynyl; or a pharmaceutically acceptable salt, solvate, metabolite, prodrug, bioisostere, or protected form thereof, for use in the treatment or prevention of a sleep disorder, together with methods of treating or preventing a sleep disorder in a subject or of treating or preventing a symptom or co-morbidity associated with a sleep disorder.

The present technology is generally directed to methods for addressing a patient's sleep apnea. In some embodiments, the method includes identifying one or more locations or sites at which the patient experiences tissue collapse, using the identified tissue collapse sites to select one or more target tissues associated with this tissue collapse, and positioning one or more signal delivery devices to deliver modulation signals to the one or more target tissues.

The object of the present invention is to provide an eye mask system. [Solution] An eye mask system for providing respiratory pressure therapy (RPT) for the treatment of sleep-disordered breathing, comprising: an eye mask configured to cover the user's eyes when in use; and one or more transducers configured to affect the user's sleep and / or detect the user or the user's sleep characteristics. The eye mask system may include a connection port for receiving a pressurized airflow or flow generator, and the eye mask system may include a plenum chamber, a seal-forming structure for forming a seal with the user's facial area, and a vent for allowing gas exhaled by the user to flow outwards. The eye mask system may operate in a non-therapeutic mode in which RPT is not provided to the user, and in a therapeutic mode in which RPT is provided to the user.

Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of a norepinephrine reuptake inhibitor (NRI) and a muscarinic receptor antagonist.

Pharmaceutical compositions comprising (i) a P2X3 receptor antagonist and (ii) a carbonic anhydrase inhibitor (CAI), and methods of treating sleep apnea and conditions associated with pharyngeal airway collapse are described herein.

Techniques for addressing sleep disorders are provided. A system includes a nerve stimulator that is configured to deliver stimulation energy to a nerve of a sleeping patient. A system includes a sensor for gather data from the sleeping patient and a controller for processing the data. The controller is configured to cause the stimulation energy that is provided to be adjusted based on the sensed data.